MTOR and Hyperglycemia: In order to study the role of AMPK/mTOR in mitophagy inhibition, we further treated NRK-52E cells in hyperglycemic group (16.7 mmol/L) with AMPK activator AICAR or mTOR inhibitor rapamycin (RAPA), and detected decreased ROS production, improved MMP, increased LC3-II/LC3-I ratio and decreased P62 and BNIP3L/Nix compared with those in hyperglycemia group (P < 0.05) (Figure 7).